--NTX1088 Clinical Trial Has Added a KEYTRUDA® Combination Therapy Arm and Expanded to the Newly Launched Ochsner MD Anderson Cancer Center in Louisiana and Four Other Global Sites--

--NTX1088临床试验增加了KEYTRUDA®联合治疗组，并扩展到路易斯安那州新成立的Ochsner MD Anderson癌症中心和其他四个全球网站--

FORT LEE, N.J., Dec. 18, 2023 /PRNewswire/ -- Nectin Therapeutics Ltd., (Nectin), a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology treatments, announced today that it has progressed its Phase 1 clinical trial of NTX1088 to include a combination therapy arm with the immune-oncology drug KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, and expanded the clinical trial to five global sites..

新泽西州李堡，2023年12月18日/PRNewswire/--Nectin Therapeutics Ltd.（Nectin）是一家开发新型靶向免疫疗法的生物技术公司，旨在解决对已批准的免疫肿瘤学治疗的耐药性，该公司今天宣布，其NTX1088的1期临床试验已取得进展，其中包括与免疫肿瘤学药物KEYTRUDA®（pembrolizumab）的联合治疗组，默克公司的抗PD-1疗法，并将临床试验扩展到全球五个地点。。

The clinical trial sites include City of Hope in California, Sheba Medical Center and Hadassah Medical Center in Israel, along with MD Anderson Cancer Center in Houston, Texas and Ochsner MD Anderson Cancer Center in Louisiana. Notably, the NTX1088 clinical trial is the first to enroll patients at the new Ochsner MD Anderson Cancer Center partnership that was established to ensure that Ochsner cancer patients have access to the most advanced care, including to clinical trials of innovative therapies..

临床试验地点包括加利福尼亚州的希望之城、以色列的Sheba医疗中心和Hadassah医疗中心，以及德克萨斯州休斯顿的MD安德森癌症中心和路易斯安那州的Ochsner MD安德森癌症中心。值得注意的是，NTX1088临床试验是首次在新的Ochsner MD Anderson癌症中心合作伙伴关系中招募患者，该合作伙伴关系旨在确保Ochsner癌症患者获得最先进的护理，包括创新疗法的临床试验。。

'As a leader in cancer care, Ochsner MD Anderson Cancer Center is committed to providing world-class care to the southeastern Louisiana community,' said Dr. Marc Matrana, Director, Precision Cancer Therapies and Research Program at Ochsner. 'Part of that commitment is ensuring that our patients have access to clinical trials of innovative new cancer therapies.

“作为癌症护理领域的领导者，Ochsner MD Anderson癌症中心致力于为路易斯安那州东南部社区提供世界级的护理，”Ochsner精准癌症治疗和研究项目主任马克·马特拉纳博士说这一承诺的一部分是确保我们的患者能够获得创新新型癌症疗法的临床试验。

We are impressed by the promising preclinical data and the novel mechanism of action of PVR blockade, and we are delighted to join with Nectin Therapeutics to support the Phase 1 trial of NTX1088.' .

我们对有希望的临床前数据和PVR阻断的新作用机制印象深刻，我们很高兴加入Nectin Therapeutics以支持NTX1088的1期试验。

NTX1088 is Nectin's first-in-class lead candidate – a highly potent monoclonal antibody directed against PVR (CD155), a transmembrane protein expressed on cancer cells and associated with resistance to PD1 and PDL1 immune checkpoint inhibitors. PVR blockade by NTX1088 is the first and only therapeutic approach aimed at restoring the antitumor immune activity of DNAM1 (CD226).

NTX1088是Nectin的第一个一流的主要候选物-一种针对PVR（CD155）的高效单克隆抗体，PVR是一种在癌细胞上表达的跨膜蛋白，与PD1和PDL1免疫检查点抑制剂的耐药性有关。NTX1088阻断PVR是第一种也是唯一一种旨在恢复DNAM1（CD226）抗肿瘤免疫活性的治疗方法。

DNAM1 is a cell surface glycoprotein, central to the function of T-cells and NK cells, which are degraded by PVR on tumor cells. Restoring the expression and activation of DNAM1 by blocking PVR results in increased antitumor activity from T-cells and NK cells. Additionally, PVR blockade by NTX1088 further stimulates an antitumor immune response by preventing the suppressing signaling of several immune checkpoint receptors, including TIGIT and CD96.

DNAM1是一种细胞表面糖蛋白，对T细胞和NK细胞的功能至关重要，它们被肿瘤细胞上的PVR降解。通过阻断PVR恢复DNAM1的表达和活化导致T细胞和NK细胞的抗肿瘤活性增加。此外，NTX1088对PVR的阻断通过阻止几种免疫检查点受体（包括TIGIT和CD96）的抑制信号传导来进一步刺激抗肿瘤免疫应答。

NTX1088 is currently being clinically evaluated as a monotherapy and in combination with KEYTRUDA® in patients with advanced solid tumors..

NTX1088目前正在临床评估为单一疗法，并与KEYTRUDA®联合用于晚期实体瘤患者。。

'We are encouraged by the rapid progress of our NTX1088 clinical program,' said Dr. Keren Paz, Chief Development Officer of Nectin Therapeutics. 'Our collaboration with Merck, and the rapid expansion of our clinical trial sites significantly increase cancer patients' access to the trial. We value the commitment of our new partners to the mission of developing life-saving therapies and look forward to advancing innovative medicines to improve the lives of cancer patients.'.

Nectin Therapeutics首席开发官科伦·帕兹（KerenPaz）博士说，我们对NTX1088临床项目的快速进展感到鼓舞我们与默克公司的合作，以及我们临床试验地点的快速扩大，大大增加了癌症患者获得试验的机会。我们重视我们的新合作伙伴对开发挽救生命疗法的使命的承诺，并期待着推进创新药物以改善癌症患者的生活。”。

The NTX1088 Phase 1 trial is being conducted with support from The Cancer Focus Fund, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center. The fund provides investment support to advance promising cancer therapies along with the clinical trial expertise and infrastructure of MD Anderson Cancer Center sites. .

NTX1088 1期试验正在癌症焦点基金的支持下进行，该基金是与德克萨斯大学MD安德森癌症中心合作成立的独特投资基金。该基金提供投资支持，以推进有前景的癌症治疗，以及MD安德森癌症中心网站的临床试验专业知识和基础设施。。

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

KEYTRUDA®是美国新泽西州拉威市默克公司股份有限公司子公司默克夏普多姆有限责任公司的注册商标。

About NTX1088NTX1088 is a first-in-class monoclonal antibody directed against a key immune checkpoint, PVR (CD155), currently in a Phase I clinical trial. NTX1088 blocks the interaction between PVR and DNAM1 (CD226), a transmembrane molecule involved in the activation of anti-cancer T-cells and NK cells.

关于NTX1088NTX1088是针对关键免疫检查点PVR（CD155）的一流单克隆抗体，目前正在进行I期临床试验。NTX1088阻断PVR和DNAM1（CD226）之间的相互作用，DNAM1是一种参与抗癌T细胞和NK细胞活化的跨膜分子。

By preventing internalization and degradation of DNAM1, NTX1088 leads to restoration of DNAM1 expression on the surface of immune cells, resulting in robust antitumor activity. NTX1088 also blocks PVR interactions with its other ligands, such as TIGIT and CD96, preventing their immune inhibitory signaling.

通过防止DNAM1的内化和降解，NTX1088导致免疫细胞表面DNAM1表达的恢复，从而产生强大的抗肿瘤活性。NTX1088还阻断PVR与其其他配体（如TIGIT和CD96）的相互作用，阻止其免疫抑制信号传导。

NTX1088 demonstrated superior antitumor activity compared to approved and investigational immune checkpoint inhibitors in preclinical models and had a favorable safety profile in non-human primates. NTX1088 is currently being clinically evaluated as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors..

与临床前模型中批准的和研究性免疫检查点抑制剂相比，NTX1088表现出优异的抗肿瘤活性，并且在非人灵长类动物中具有良好的安全性。NTX1088目前正在临床上作为单一疗法进行评估，并与KEYTRUDA®（pembrolizumab）联合用于晚期实体瘤患者。。

About Nectin TherapeuticsNectin Therapeutics is a clinical stage biotechnology company devoted to transforming the lives of cancer patients by leveraging unique insights into nectin pathways to develop the next generation of immune oncology (IO) therapies. The company's differentiated therapies have the potential to set new standards for efficacy and patient response rates across various difficult-to-treat cancers.

关于Nectin Therapeutics Nectin Therapeutics是一家临床阶段的生物技术公司，致力于通过利用对Nectin途径的独特见解来开发下一代免疫肿瘤学（IO）疗法来改变癌症患者的生活。该公司的差异化疗法有可能为各种难以治疗的癌症的疗效和患者反应率制定新的标准。

Nectin's technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody drug conjugates (ADCs). It has a world-class scientific and management team with deep experience in oncology drug development and successful track records in building biotechnology companies and developing innovative therapies.

Nectin的技术通过多种新型单克隆抗体和抗体-药物偶联物（ADC）的管道解决了当前IO疗法的主要逃逸机制。它拥有一支世界级的科学和管理团队，在肿瘤药物开发方面拥有丰富经验，在建立生物技术公司和开发创新疗法方面取得了成功。

Nectin Therapeutics is a venture-backed, privately held company, funded by aMoon Fund, Peregrine Ventures, IBF, Integra Holdings, the Myeloma Investment Fund and the Cancer Focus Fund..

Nectin Therapeutics是一家由aMoon Fund、Peregrine Ventures、IBF、Integra Holdings、骨髓瘤投资基金和癌症焦点基金资助的风险投资私人控股公司。。

Contacts:

联系人：

Media Relations:Barbara LindheimBLL Partners for Nectin Therapeutics[email protected]+1 917 355-9234

媒体关系：Barbara LindheimBLL Nectin Therapeutics合作伙伴[电子邮件保护]+1 917 355-9234

SOURCE Nectin Therapeutics

来源Nectin Therapeutics